CAR T-cell Therapy | Specialty

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Shaughnessy Speaks to the Rapidly Evolving Role of CAR T-cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.

Tisagenlecleucel Shows Clinically Meaningful Benefit in Relapsed/Refractory Follicular Lymphoma

August 4th 2020

Tisagenlecleucel was found to elicit clinically meaningful activity in patients with relapsed/refractory follicular lymphoma, meeting the phase 2 ELARA trial’s primary end point of complete response rate.

Dr. Shaughnessy on Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 4th 2020

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.

FDA Approval Sought for Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma

July 29th 2020

A biologics license application has been submitted to the FDA for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory MCL

July 24th 2020

The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies

July 22nd 2020

The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.

Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

July 17th 2020

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

Liso-Cel Takes Step Toward EU Approval in B-Cell Lymphomas

July 17th 2020

The European Medicines Agency has validated a Marketing Authorization Application for the CD19-directed CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma following at least 2 prior therapies.

CAR T Pioneers Describe Challenges Faced in Cancer

July 16th 2020

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

FDA Issues Clinical Hold on MELANI-01 Trial With UCARTCS1A in Myeloma

July 7th 2020

The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma.

Dr. Munshi on Next Steps With Idecabtagene Vicleucel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

July 2nd 2020

Developing CAR T-Cell Trials

July 2nd 2020

Allogenic CAR T-Cell Therapy in Lymphoma

July 2nd 2020

CAR T-Cell Therapy’s Future for Lymphoma

July 2nd 2020

CAR T Cells and Lymphoma Adverse Events

July 2nd 2020

LBCL Therapy: The Right Therapy

July 2nd 2020

R/R NHL: Candidate Identification and Referrals

July 2nd 2020

CAR T-Cell Therapy for Follicular Lymphoma

July 2nd 2020